Yongqiang Hua1,2, Yaodong Zhu3, Jijie Zhang4, Zhenfeng Zhu1,2, Zhouyu Ning1,2, Hao Chen1,2, Luming Liu1,2, Zhen Chen1,2, Zhiqiang Meng5,6. 1. Minimally Invasive Treatment Center, Fudan University Shanghai Cancer Center, Shanghai, China. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. 3. Chinese Integrative Medicine Oncology Department, First Affiliated Hospital of Medical University of Anhui, Hefei City, China. 4. Oncology Department, Danyang People's Hospital of Jiangsu Province, Danyang City, China. 5. Minimally Invasive Treatment Center, Fudan University Shanghai Cancer Center, Shanghai, Chinashaizhenchen@126.com. 6. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Chinashaizhenchen@126.com.
Abstract
BACKGROUND/AIMS: Although oxaliplatin is one of the most effective chemotherapeutic drugs used to treat colorectal cancer (CRC), long-term administration usually induces acquired drug resistance during the course of treatment. Thus, there is an urgent need to explore novel strategies to improve the efficiency of cancer therapy. The aim of this study was to explore the effect of microRNA-122 (miR-122) on reversing oxaliplatin resistance in CRC. METHODS: The expression of miR-122 in CRC cells was examined by quantitative reverse transcriptase real-time PCR. The cytotoxicity of oxaliplatin against CRC cells was evaluated by Cell Counting Kit-8 assays. Mitochondrial membrane potentials and cell apoptotic rates were measured by flow cytometry. Cellular protein expression and interactions were detected by western blot and co-immunoprecipitation. RESULTS: Established oxaliplatin-resistant SW480 and HT29 cells (SW480/OR and HT29/OR) expressed significantly higher levels of X-linked inhibitor of apoptosis protein (XIAP) and lower levels of miR-122 compared with normal SW480 and HT29 cells, respectively. Our results showed that the downregulation of miR-122 was responsible for the overexpression of XIAP in these oxaliplatin-resistant CRC cells. We then found that the recovery of miR-122 expression can sensitize SW480/OR and HT29/OR cells to oxaliplatin-mediated apoptosis through the inhibition of XIAP expression. CONCLUSION: Upregulation of XIAP in CRC cells is responsible for the acquired resistance to oxaliplatin. Furthermore, miR-122 reversed oxaliplatin resistance in CRC by targeting XIAP.
BACKGROUND/AIMS: Although oxaliplatin is one of the most effective chemotherapeutic drugs used to treat colorectal cancer (CRC), long-term administration usually induces acquired drug resistance during the course of treatment. Thus, there is an urgent need to explore novel strategies to improve the efficiency of cancer therapy. The aim of this study was to explore the effect of microRNA-122 (miR-122) on reversing oxaliplatin resistance in CRC. METHODS: The expression of miR-122 in CRC cells was examined by quantitative reverse transcriptase real-time PCR. The cytotoxicity of oxaliplatin against CRC cells was evaluated by Cell Counting Kit-8 assays. Mitochondrial membrane potentials and cell apoptotic rates were measured by flow cytometry. Cellular protein expression and interactions were detected by western blot and co-immunoprecipitation. RESULTS: Established oxaliplatin-resistant SW480 and HT29 cells (SW480/OR and HT29/OR) expressed significantly higher levels of X-linked inhibitor of apoptosis protein (XIAP) and lower levels of miR-122 compared with normal SW480 and HT29 cells, respectively. Our results showed that the downregulation of miR-122 was responsible for the overexpression of XIAP in these oxaliplatin-resistant CRC cells. We then found that the recovery of miR-122 expression can sensitize SW480/OR and HT29/OR cells to oxaliplatin-mediated apoptosis through the inhibition of XIAP expression. CONCLUSION: Upregulation of XIAP in CRC cells is responsible for the acquired resistance to oxaliplatin. Furthermore, miR-122 reversed oxaliplatin resistance in CRC by targeting XIAP.
Authors: Marta Sánchez-Díez; Nicolás Alegría-Aravena; Marta López-Montes; Josefa Quiroz-Troncoso; Raquel González-Martos; Adrián Menéndez-Rey; José Luis Sánchez-Sánchez; Juan Manuel Pastor; Carmen Ramírez-Castillejo Journal: Biomedicines Date: 2022-05-06
Authors: Soyeon Jeong; Bu Gyeom Kim; Dae Yeong Kim; Bo Ram Kim; Jung Lim Kim; Seong Hye Park; Yoo Jin Na; Min Jee Jo; Hye Kyeong Yun; Yoon A Jeong; Hong Jun Kim; Sun Il Lee; Han Do Kim; Dae Hyun Kim; Sang Cheul Oh; Dae-Hee Lee Journal: Cancers (Basel) Date: 2019-06-05 Impact factor: 6.639
Authors: Eman Radwan; Asmaa S Shaltout; Shima Gafar Mansor; Engy A Shafik; Wael A Abbas; Mahmoud Refaat Shehata; Maha Ali Journal: Mol Biol Rep Date: 2021-06-16 Impact factor: 2.316